These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 16157792

  • 1. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.
    Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD.
    Hypertension; 2005 Oct; 46(4):975-81. PubMed ID: 16157792
    [Abstract] [Full Text] [Related]

  • 2. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension.
    Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, Hammock BD, Busse R, Fleming I.
    Hypertension; 2005 Apr; 45(4):759-65. PubMed ID: 15699457
    [Abstract] [Full Text] [Related]

  • 3. Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension.
    Elmarakby AA, Quigley JE, Pollock DM, Imig JD.
    Hypertension; 2006 Mar; 47(3):557-62. PubMed ID: 16415373
    [Abstract] [Full Text] [Related]

  • 4. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats.
    Olearczyk JJ, Quigley JE, Mitchell BC, Yamamoto T, Kim IH, Newman JW, Luria A, Hammock BD, Imig JD.
    Clin Sci (Lond); 2009 Jan; 116(1):61-70. PubMed ID: 18459944
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Targeting arachidonic acid pathway to prevent programmed hypertension in maternal fructose-fed male adult rat offspring.
    Tain YL, Lee WC, Wu KLH, Leu S, Chan JYH.
    J Nutr Biochem; 2016 Dec; 38():86-92. PubMed ID: 27732913
    [Abstract] [Full Text] [Related]

  • 7. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension.
    Li J, Carroll MA, Chander PN, Falck JR, Sangras B, Stier CT.
    Front Biosci; 2008 May 01; 13():3480-7. PubMed ID: 18508449
    [Abstract] [Full Text] [Related]

  • 8. Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats.
    Koeners MP, Wesseling S, Ulu A, Sepúlveda RL, Morisseau C, Braam B, Hammock BD, Joles JA.
    Am J Physiol Endocrinol Metab; 2011 Apr 01; 300(4):E691-8. PubMed ID: 21266668
    [Abstract] [Full Text] [Related]

  • 9. Early postnatal treatment with soluble epoxide hydrolase inhibitor or 15-deoxy-Δ(12,14)-prostagandin J2 prevents prenatal dexamethasone and postnatal high saturated fat diet induced programmed hypertension in adult rat offspring.
    Lu PC, Sheen JM, Yu HR, Lin YJ, Chen CC, Tiao MM, Tsai CC, Huang LT, Tain YL.
    Prostaglandins Other Lipid Mediat; 2016 Jul 01; 124():1-8. PubMed ID: 27210044
    [Abstract] [Full Text] [Related]

  • 10. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension.
    Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD.
    Hypertension; 2002 Feb 01; 39(2 Pt 2):690-4. PubMed ID: 11882632
    [Abstract] [Full Text] [Related]

  • 11. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats.
    Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD.
    J Cardiovasc Pharmacol; 2005 Dec 01; 46(6):842-8. PubMed ID: 16306811
    [Abstract] [Full Text] [Related]

  • 12. Soluble epoxide hydrolase inhibition ameliorates proteinuria-induced epithelial-mesenchymal transition by regulating the PI3K-Akt-GSK-3β signaling pathway.
    Liang Y, Jing Z, Deng H, Li Z, Zhuang Z, Wang S, Wang Y.
    Biochem Biophys Res Commun; 2005 Dec 01; 463(1-2):70-5. PubMed ID: 25986738
    [Abstract] [Full Text] [Related]

  • 13. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats.
    Huang H, Morisseau C, Wang J, Yang T, Falck JR, Hammock BD, Wang MH.
    Am J Physiol Renal Physiol; 2007 Jul 01; 293(1):F342-9. PubMed ID: 17442729
    [Abstract] [Full Text] [Related]

  • 14. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
    Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD.
    J Am Soc Nephrol; 2004 May 01; 15(5):1244-53. PubMed ID: 15100364
    [Abstract] [Full Text] [Related]

  • 15. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection.
    Simpkins AN, Rudic RD, Schreihofer DA, Roy S, Manhiani M, Tsai HJ, Hammock BD, Imig JD.
    Am J Pathol; 2009 Jun 01; 174(6):2086-95. PubMed ID: 19435785
    [Abstract] [Full Text] [Related]

  • 16. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension.
    Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD.
    Am J Physiol Renal Physiol; 2009 Sep 01; 297(3):F740-8. PubMed ID: 19553349
    [Abstract] [Full Text] [Related]

  • 17. Soluble epoxide hydrolase inhibitor enhances synaptic neurotransmission and plasticity in mouse prefrontal cortex.
    Wu HF, Yen HJ, Huang CC, Lee YC, Wu SZ, Lee TS, Lin HC.
    J Biomed Sci; 2015 Oct 22; 22():94. PubMed ID: 26494028
    [Abstract] [Full Text] [Related]

  • 18. Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase.
    Kim IH, Nishi K, Tsai HJ, Bradford T, Koda Y, Watanabe T, Morisseau C, Blanchfield J, Toth I, Hammock BD.
    Bioorg Med Chem; 2007 Jan 01; 15(1):312-23. PubMed ID: 17046265
    [Abstract] [Full Text] [Related]

  • 19. Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure.
    Merabet N, Bellien J, Glevarec E, Nicol L, Lucas D, Remy-Jouet I, Bounoure F, Dreano Y, Wecker D, Thuillez C, Mulder P.
    J Mol Cell Cardiol; 2012 Mar 01; 52(3):660-6. PubMed ID: 22155238
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic effects of the soluble epoxide hydrolase (sEH) inhibitor AUDA on atherosclerotic diseases.
    Zhang J, Liu YS, Lu QH.
    Pharmazie; 2015 Jan 01; 70(1):24-8. PubMed ID: 25975094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.